Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in adults with acute spinal cord injury ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

To earn CME related to this news article, click here. April 20, 2009 — A single 5-mg intravenous infusion of zoledronic acid was at least as effective and more acceptable to patients than 5 mg of oral ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

BRAMPTON, Ontario--(BUSINESS WIRE)--Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL ...

Please provide your email address to receive an email when new articles are posted on . Graeme Jones, PhD, and colleagues randomly assigned 223 patients with symptomatic knee OA and subchondral bone ...

Zoledronic acid, while a bisphosphonate itself, is much more potent, and needs only to be given in a once-yearly infusion. In this randomised controlled trial, Professor David M Reid, University of ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Bisphosphonates are the most commonly used therapeutic agents for Paget's disease. Although bisphosphonates are effective in normalizing the biochemical markers that cause the erratic bone turnover ...

The oral bisphosphonate risedronate is currently used to treat patients with Paget's disease. Therapy, however, requires daily oral dosing for 2–6 months in a complex regimen that could result in ...

Bisphosphonates are being used increasingly for the prevention and treatment of osteoporosis, hypercalcemia of malignant disease, and other disorders of bone metabolism. Known ocular complications of ...